Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05856994 · ClinicalTrials.gov registry record · Phase 1
Clinical Assessment of Protopic® Ointment in Deep Partial-Thickness Burns
A Phase 1 study of Burn Injury, sponsored by Vanderbilt University Medical Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT05856994: Recruiting Phase 1 study of Burn Injury, sponsored by Vanderbilt University Medical Center.
NCT05856994 is a Phase 1 study of Burn Injury that is actively recruiting participants, run by Vanderbilt University Medical Center. The registered enrollment target is 18 participants, below the 41-participant average among 10 other Burn Injury trials with a reported enrollment target (56% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05856994, a Phase 1 study of Burn Injury, is actively recruiting participants, sponsored by Vanderbilt University Medical Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
There is currently no standard treatment to prevent burn depth conversion in partial-thickness burns. Conversion into deeper wounds is associated with higher complications and morbidity. The most common theory attributes this depth conversion to the prolonged inflammatory response that occurs after burn injury. Therefore, the investigators propose testing the safety and efficacy of tacrolimus ointment (an immunosuppressive agent) in patients with deep partial-thickness burns.
Primary Outcome
Clinical burn wound assessment
Conditions Studied
Interventions
- DRUG Tacrolimus ointment
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2024-09-19 |
| Est. Completion | 2028-06-01 |
| Phase | Phase 1 |
What NCT05856994 shows while recruiting
NCT05856994 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 41-participant average among 10 other Burn Injury trials with a reported enrollment target (56% lower).
The record links to 1 condition, with Burn Injury appearing as the primary indexed condition, and to 1 intervention - of which Tacrolimus ointment is the first listed.
NCT05856994 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT05856994 about?
NCT05856994 is a clinical study titled "Clinical Assessment of Protopic® Ointment in Deep Partial-Thickness Burns". There is currently no standard treatment to prevent burn depth conversion in partial-thickness burns. Conversion into deeper wounds is associated with higher complications and morbidity. The most common theory attributes this depth conversion to the prolonged inflammatory response that occurs after ...
What is the current status of trial NCT05856994?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2024-09-19. Estimated completion is 2028-06-01.
What conditions does trial NCT05856994 study?
This clinical trial studies the following conditions: Burn Injury.
What interventions are being tested in trial NCT05856994?
The interventions under investigation include: Tacrolimus ointment (DRUG).
Who is sponsoring clinical trial NCT05856994?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05856994 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Burn Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05856994's enrollment target sits among peer trials
18 11th of 10 the lowest of 10 other Burn Injury trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Burn Injury trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Effect of Simulated Burn Injury on Post Exercise Recovery in Hot Environments
RECRUITING · NA
-
VR-PMR for Post-Burn Symptoms
RECRUITING · NA
-
Cardiovascular Responses in Burn Survivors During Exercise
RECRUITING · NA
-
Skin Wetting in Burn Survivors
RECRUITING · NA
-
IEEM- Work:Rest Cycles in Burn Survivors- Humidity
RECRUITING
-
Amino Acid Supplementation in Recovery From Severe Burns
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI